Skip to content

Beam Therapeutics BEAM Book value per share

Book value per share at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$75.54+18.8%
Arrowhead Research logo
Arrowhead ResearchARWR
$4.31-15.2%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$18.89-11.2%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$3.75+93.9%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$2.19-1.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$11.70-34.9%

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.42B+24.5%

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Calculated from Beam Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's book value per share?
Beam Therapeutics (BEAM) reported book value per share of $11.28 in Q1 2026.
How has Beam Therapeutics's book value per share changed year-over-year?
Beam Therapeutics's book value per share decreased by 12.2% year-over-year, from $12.84 to $11.28.
What is the long-term trend for Beam Therapeutics's book value per share?
Over 5 years (2020 to 2025), Beam Therapeutics's book value per share has grown at a 19.0% compound annual growth rate (CAGR), from $5.25 to $12.52.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.